Press Releases August 6, 2026 07:00 AM

USA Rare Earth Announces Date for Release of Second Quarter 2026 Results and Conference Call

USA Rare Earth schedules Q2 2026 earnings release and conference call for August 10, highlighting progress in building a fully integrated rare earth and magnet supply chain.

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
USAR

USA Rare Earth, a Nasdaq-listed company focused on rare earth metals and permanent magnets, announced it will release its financial results for Q2 2026 on August 10, followed by a conference call to discuss outcomes and operational progress. The company is advancing its integrated supply chain spanning mining, metal production, and magnet manufacturing across the US and other countries, serving critical sectors such as aerospace, defense, and energy.

USA Rare Earth Announces Date for Release of Second Quarter 2026 Results and Conference Call
USAR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Earnings release scheduled for August 10, 2026, including a conference call for investor discussion.
  • USA Rare Earth operates a complete rare earth value chain including mining, alloy production, and magnet manufacturing in multiple countries.
  • The company supports sectors such as aerospace, defense, semiconductor, energy, AI, healthcare, and industrial through a secure, Western-aligned supply chain.

STILLWATER, Okla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (the Company), today announced that it will release financial results for the quarterly period ended June 30, 2026, after U.S. markets close on Monday, August 10, 2026. Additionally, the Company will host a conference call that afternoon to discuss the results and related matters.

EARNINGS RELEASE
Monday, August 10, 2026 (after market close)

LIVE CONFERENCE CALL
Monday, August 10, 2026, at 5 p.m. ET
US/Canada Toll-Free: +1 (833) 890-8030
International: +1 (412) 564-6268

CONFERENCE CALL REPLAY
Expiration: September 10, 2026
US/Canada Toll-Free: +1 (855) 669-9658
International Toll: +1 (412) 317-0088
Access code: 7520719

Investors may also access the live call and the replay over the internet on the “Events” page of the Company’s investor website located at www.usare.com or at https://event.choruscall.com/mediaframe/webcast.html?webcastid=SCYm7iDr.

For more information, please visit USARE.com.

About USA Rare Earth

USA Rare Earth, Inc. (Nasdaq: USAR) is building a fully integrated rare earth and permanent magnet value chain across the United States, the United Kingdom, France and Brazil. Through its ownership of Less Common Metals (LCM), one of the world’s leading producers of rare earth metals and alloys, its development of magnet manufacturing capacity in Stillwater, Oklahoma, the Pela Ema mine in Brazil (subject to closing the SVG transaction) and the Round Top deposit in Texas, USA Rare Earth operates across the entire value chain from mining to metal-making, alloy production and neodymium magnet manufacturing. USA Rare Earth is establishing a secure, Western-aligned supply of materials essential to the aerospace and defense, semiconductor, energy, data center, physical AI, mobility, healthcare and industrial sectors.

For more information, visit www.usare.com.

Investor Relations Contact
J.B. Lowe, CFA
VP, Head of Investor Relations
[email protected]

Media Relations Contact
Collected Strategies
Dan Moore / Scott Bisang
[email protected]


Risks

  • Completion of the Pela Ema mine acquisition in Brazil depends on closing the SVG transaction, which may present uncertainties.
  • Market demand and pricing volatility for rare earth metals and permanent magnets may affect financial performance.
  • Geopolitical or supply chain disruptions could impact operations across international sites, affecting global supply commitments.

More from Press Releases

Safe Harbor's Cannabis-Focused 401(k) Plan Gains Early Adoption as Canopy HR Names It the Recommended Retirement Solution for its Clients Aug 6, 2026 Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update Aug 6, 2026 ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update Aug 6, 2026 Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma Aug 6, 2026 Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. Aug 6, 2026